FEBICO Business Summary

Far East Bio-Tec Co., Ltd. (FEBICO) is a vertically integrated biotechnology firm specializing in the large-scale cultivation and commercialization of microalgae-based solutions. The company generates revenue through three primary channels: the sale of proprietary branded health supplements (e.g., Apogen, Bpogen, and Sorokina), the supply of raw materials like organic Chlorella and Spirulina, and the provision of contract manufacturing services (OEM/ODM) for global private labels. Its business segments are divided into Microalgae Cultivation, Precision Nutrition, and Biomedical Research, the latter focusing on high-value phycobiliproteins for clinical diagnostics and microalgae exosomes for the premium skincare market. FEBICO competes directly with major industry players such as Cyanotech Corporation, DIC Corporation (Earthrise Nutritionals), and Taiwan Chlorella Manufacturing Company (TCMC). Within this landscape, FEBICO positions itself as a science-driven innovator, leveraging nearly 50 years of R&D to produce clinically validated, patented antiviral and metabolic health products. Leadership is centered under Founder and Chairman C. C. Chiueh (also known as Algae Chueh), a chemical engineering graduate from National Cheng Kung University who established the company in 1976. Chiueh continues to serve as the primary executive and General Manager, overseeing a team with deep pedigree in microalgae biotechnology and process engineering. The leadership team is supported by a strategic partnership with Shiny Brands Group Co., Ltd., which acquired a 3.31% stake in the company in late 2024 to accelerate the commercialization of FEBICO’s technological breakthroughs in exosomes. The board and executive management maintain a strong focus on international quality standards, operating GMP-certified facilities in the Pingtung Agricultural Biotechnology Park to meet surging global demand for evidence-based natural health solutions.